The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma

被引:3
|
作者
Zhang, Lishuo [1 ]
Di, Longjiang [2 ]
Liu, Jinhui [3 ]
Lei, Xianli [4 ]
Gu, Maoli [1 ]
Zhang, Wenjing [3 ]
Wang, Yufu [3 ]
机构
[1] Harbin Med Univ, Dept Urol, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China
[2] Southern Med Univ, Coll Basic Med, Guangzhou, Guangdong, Peoples R China
[3] Harbin Med Univ, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China
[4] Harbin Med Univ, Harbin, Heilongjiang, Peoples R China
基金
中国国家自然科学基金;
关键词
clear cell renal cell carcinoma; long non-coding RNA; cuproptosis; prognosis; immunotherapy; CLASSIFICATION;
D O I
10.3389/fgene.2023.1039813
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cuproptosis is a new form of cell death, the second form of metal ion-induced cell death defined after ferroptosis. Recently, cuproptosis has been suggested to be associated with tumorigenesis. However, the relationship between cuproptosis and patient prognosis in clear cell renal cell carcinoma (ccRCC) in the context of immunotherapy remains unknown. The aim of this study was to investigate the correlation between cuproptosis-related long non-coding RNA (lncRNA) and ccRCC in terms of immunity as well as prognosis. Clinical information on lncRNAs associated with differences in cuproptosis genes in ccRCC and normal tissues was collected from The Cancer Genome Atlas (TCGA) dataset. Univariate Cox regression was used to screen lncRNAs. A total of 11 lncRNAs closely associated with cuproptosis were further screened and established using the least absolute shrinkage and selection operator (LASSO) algorithm and multivariate Cox regression, and the samples were randomly divided into training and test groups. A risk prognostic model was constructed using the training group, and the model was validated using the test group. We investigated the predictive ability of the prognostic risk model in terms of clinical prognosis, tumor mutation, immune escape, immunotherapy, tumor microenvironment, immune infiltration levels, and tumor drug treatment of ccRCC. Using the median risk score, patients were divided into low and high-risk groups. Kaplan-Meier curves showed that the overall survival (OS) of patients in the high-risk group was significantly worse than low-risk group (p < 0.001). Receiver operating characteristic (ROC) curves further validated the reliability of our model. The model consistently and accurately predicted prognosis at 1, 3, and 5 years, with an AUC above 0.7. Tumor cell genes generally precede morphological abnormalities; therefore, the model we constructed can effectively compensate for the traditional method of evaluating the prognosis of patients with renal cancer, and our model was also clinically meaningful in predicting ccRCC staging. In addition, lower model risk scores determined by mutational load indicated a good chance of survival. The high-risk group had greater recruitment of immune cells, while the anti-immune checkpoint immunotherapy was less efficacious overall than that of the low-risk group. Tumor and immune-related pathways were enriched, and anti-tumor agents were selected to improve the survival of ccRCC. This prognostic risk model is based on the levels of cuproptosis-associated lncRNAs and provides a new perspective in the clinical assessment and precise treatment of ccRCC.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma
    Wang, Hu
    Yang, Zhan
    He, Xingyu
    Guo, Fengran
    Sun, Hao
    Xu, Sen
    Xu, Chao
    Wang, Zhu
    Wen, Hongzhuang
    Teng, Zhihai
    Wang, Yaxuan
    Han, Zhenwei
    BMC CANCER, 2023, 23 (01)
  • [22] Characterization of cuproptosis signature in clear cell renal cell carcinoma by single cell and spatial transcriptome analysis
    Zou, Xiaohong
    Liu, Xiaoqing
    Wang, Huiting
    Li, Zhenhua
    Zhou, Chen
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [23] The Immune-Related Gene HCST as a Novel Biomarker for the Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma
    Zhou, Yongying
    Wang, Xiao
    Zhang, Weibing
    Liu, Huiyong
    Liu, Daoquan
    Chen, Ping
    Xu, Deqiang
    Liu, Jianmin
    Li, Yan
    Zeng, Guang
    Li, Mingzhou
    Wu, Zhonghua
    Zhang, Yingao
    Wang, Xinghuan
    DiSanto, Michael E.
    Zhang, Xinhua
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] Identification of cuproptosis-related lncRNAs signature for predicting the prognosis in patients with kidney renal clear cell carcinoma
    He, Ya
    Zhang, Hongxia
    Li, Jingang
    Zhou, Hui
    Wang, Fei
    Zhang, Guangliang
    Wen, Yuetao
    JOURNAL OF GENETIC ENGINEERING AND BIOTECHNOLOGY, 2024, 22 (01):
  • [25] Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma
    Zhou, Libin
    Fang, Hualong
    Guo, Fei
    Yin, Min
    Long, Huimin
    Weng, Guobin
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (08)
  • [26] A cuproptosis-associated long non-coding RNA signature for the prognosis and immunotherapy of lung squamous cell carcinoma
    Hou, Chunlan
    Wu, Xiuping
    Li, Caoyang
    Wang, Chao
    Liu, Jinbo
    Luo, Qing
    BIOMOLECULES AND BIOMEDICINE, 2023, 23 (04): : 624 - 633
  • [27] Identification of a cuproptosis-related lncRNA signature to predict the prognosis and immune landscape of head and neck squamous cell carcinoma
    Huang, Juntao
    Xu, Ziqian
    Yuan, Zhechen
    Teh, Bing Mei
    Zhou, Chongchang
    Shen, Yi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma
    Liang, Shuang
    Ji, Lanting
    Yu, Zhenyuan
    Cheng, Yahsin
    Gao, Ruifang
    Yan, Wenpeng
    Zhang, Fang
    HEREDITAS, 2024, 161 (01)
  • [29] The vasculogenic mimicry related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma
    Gu, Yuming
    Huang, Qinqin
    Wang, Yun
    Wang, Haixia
    Xiang, Zhenhua
    Xu, Yu
    Wang, Xin
    Liu, Weiguo
    Wang, Aiju
    BMC CANCER, 2024, 24 (01)
  • [30] Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma
    Cai, Zhiyong
    He, You'e
    Yu, Zhengzheng
    Hu, Jiao
    Xiao, Zicheng
    Zu, Xiongbing
    Li, Zhenghao
    Li, Huihuang
    FRONTIERS IN IMMUNOLOGY, 2022, 13